The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0749 GMT - Fresenius investors might have overreacted to news that the FDA sent a warning letter to the German healthcare group's Kabi pharmaceutical business alerting it to what the regulator called serious violations at a U.S. facility, Citi analysts say in a research note. Fresenius Kabi said in response that no patient-safety concerns had been identified. While the letter is negative for sentiment, a warning letter doesn't come as a big surprise given that Fresenius had already flagged potential FDA action at its last earnings call, and the company expects no material impact on production or results, the analysts say. "The warning on withholding of new drug approvals until violations are fully resolved is standard warning letter language," they add. Fresenius shares rise 1.8%, after closing 4.9% lower on Tuesday. (adria.calatayud@wsj.com)

0452 GMT - CSL still generates caution at Macquarie despite the stock's recent rerate. Analysts at the investment bank keep a neutral rating on the Australia-based pharmaceutical company, observing that a 58% share-price rise over three months came despite earnings downgrades. They think that near-term catalysts will probably support the current rerating, but tell clients in a note that they are cautious on the medium-term outlook due to uncertainty over the impact on demand of complement-inhibitor therapies, albumin collections, and the process to appoint a new permanent CEO. Macquarie raises its target price on the stock 31% to 174.00 Australian dollars. Shares are up 1.4% at A$184.25. (stuart.condie@wsj.com)

0211 GMT - IHH Healthcare's recent share price weakness is likely an enhanced buying opportunity, with Fortis-related litigation concerns expected to have limited impact on operations, says Citi analyst Megat Fais in a note. IHH says it isn't subject to financial claims in the dispute involving Daiichi Sankyo and former Fortis promoters. IHH's India plans remain on track to reach 10,000 beds target by 2030-2031, while Singapore's recovery is expected to continue, he reckons. Malaysia should see growth from selective bed additions and medical tourism, while Turkey's strong demand and international patient flows are expected to continue, he adds. Citi keeps a buy rating and its target price at 10.40 ringgit. Shares are 0.1% higher at 7.88 ringgit. (yingxian.wong@wsj.com)

1419 GMT - Sterling shows little reaction after U.K. Prime Minister Andy Burnham announced plans to reform pensions in a speech Tuesday, as widely expected. From 2030 the government will adjust the triple lock on pensions, which ensures state pensions rise in line with average earnings, inflation or 2.5%, whichever is highest. Instead pensions will rise every year in line with inflation, or 2.5%. Burnham scrapped the earnings element, saying state pensions would hold their value "relative to earnings over time." He also pledged to build a national care service, create a public body to invest in the electricity grid and strengthen control of water companies. Sterling falls 0.2% to $1.3222 and is flat at 0.8573 per euro, both little changed from levels before the speech. (renae.dyer@wsj.com)

1350 GMT - Roche Holding provided an encouraging update on its plans for a new breast-cancer drug, which together with other upcoming product launches underscore the company's confidence in its growth through the end of the decade, Citi analysts say. The Swiss drugmaker signaled it is comfortable with 2027 consensus estimates for sales of its breast-cancer drug, giredestrant, of 600 million Swiss francs, Citi says in a research note. Roche plans a patient-assistance program, offering the drug for free to some patients initially to reduce access barriers with the hope of seeing a "hockey-stick" launch trajectory, the analysts say. Citi expects the sales impact to be covered by 2028, and reiterates its forecast of annual peak sales of $14.5 billion. Shares fall 1.2%. (adria.calatayud@wsj.com)

1336 GMT - Roche Holding's clinical-trial success rate has improved and research-and-development cycles shortened since the company introduced a more stringent approach to its drug pipeline after a series of failed studies in 2022, Vontobel's Stefan Schneider says. The Swiss drugmaker used an event with investors on Monday to showcase the progress it made over the past year, the analyst says in a research note. Even if Roche disclosed it is dropping development of muscle-sparing drug emugrobart for obesity, ten positive late-stage study results over the past year reassure about its future growth outlook, the analyst adds. "Today, the company has an overall smaller number of pipeline projects ongoing, but they are more carefully selected when being pushed through the clinic to the market," Vontobel says. Shares fall 1.4%. (adria.calatayud@wsj.com)

1255 GMT - Roche Holding struck an upbeat tone on its drug pipeline, but didn't deliver the guidance upgrade some expected, as it gave investors an update on its pharma business, RBC Capital Markets analysts say in a research note. The Swiss pharma group said Monday that it plans new studies for its breast-cancer drug candidate giredestrant across different treatment lines, combinations and settings of the disease. "While the breadth of the giredestrant program and broader pipeline provided encouragement around Roche's longer-term growth potential, the lack of midterm guidance update meant the event unlikely provided the incremental upside catalyst some investors had been hoping for," they add. Shares fall 1.2%. (adria.calatayud@wsj.com)

1235 GMT - Roche Holding shares trade at a premium to those of peers, which will be difficult to justify if the launches of its next drugs don't deliver on expectations, Jefferies analysts say in a research note. There were no big surprises in the Swiss drugmaker's update on its pharma business held Monday and 2027 is shaping up to be a year more focused on regulatory filings than on clinical-trial results, the analysts say. "What is now perhaps even clearer is that 2027 giredestrant and fenebrutinib launches must deliver, if approved, as key clinical catalysts don't emerge until closer to 2028," Jefferies says, referring to Roche's new drugs for breast cancer and multiple sclerosis, respectively. Shares fall 1.2%. (adria.calatayud@wsj.com)

1222 GMT - Roche Holding's research and early development is becoming more productive thanks to the integration of AI into its workflows, but it is too soon to know if the technology improves a drug candidate's chances in a clinical trial, J.P. Morgan analysts say in a research note. The Swiss drugmaker said it is using AI to speed up the process of discovering new medicines, and ultimately aims to improve the quality of those that it moves to the development phase. "While they are making significant progress enhancing the research process, whether this will lead to enhanced probability of success will only become clear as the molecules go through clinical testing over the coming 3-5 years," the analysts say. Shares fall 1.4%. (adria.calatayud@wsj.com)

1212 GMT - Roche Holding's confidence in its portfolio of medicines for obesity and diabetes seems to be growing as the Swiss drugmaker seeks an expansion into broader cardiovascular indications, UBS analysts say in a research note. "Management continues to expect a highly segmented obesity market, with orals a critical pillar both as monotherapy and in combinations, and sees oral therapies expanding the market," the analysts say. Roche believes the glucose-control performance of its enicepatide drug candidate in a recent midstage trial warrants a head-to-head comparison study against Eli Lilly's Mounjaro in diabetes, with no decision yet on a similar study in obesity, they add. Moreover, the company plans to test enicepatide for cardiac conditions, while moving two other experimental obesity drugs to late-stage studies. Shares fall 1.1%. (adria.calatayud@wsj.com)

1034 GMT - AstraZeneca's deal with Summit Therapeutics looks like a strategically smart move for the U.K. drugmaker, which adds combination options for its portfolio while keeping risk exposure low, analysts at Jefferies say in a research note. AstraZeneca is taking a 12% stake in Summit for $2 billion and entering into a research collaboration with the Miami-based company. This gives AstraZeneca's oncology portfolio a clear route to combinations with Summit's experimental drug ivonescimab, the analysts say. "We argue that the deal, which provides development optionality without the risk of a larger acquisition before key [clinical-trial] results, should be well received by investors, ensuring AZN has a seat at the table should the mechanism become globally validated," they add. AstraZeneca shares rise 1.5%. In U.S. premarket trading, Summit jumps 20%. (adria.calatayud@wsj.com)

1010 GMT - AstraZeneca's $2 billion investment in Summit Therapeutics works for both companies, UBS analysts say in a research note. For Summit, this is potentially a best-case scenario that provides external validation of its lead drug candidate ivonescimab and gives it funding to go through pivotal study results, the analysts say. The deal also brings in a strategic partner to develop Summit's medicine while allowing the company to retain future economic rights, they add. Meanwhile, AstraZeneca gains exposure to the so-called PD-1×VEGF class of cancer drugs without the cash drain of an outright acquisition, UBS says. AstraZeneca shares rise 1.5%, Summit jumps 22% in U.S. premarket trading.